A proxy advisory firm has asked shareholders of the Indian unit of Wyeth to oppose its merger deal with Pfizer Inc. (NYSE:PFE) as the share swap ratio is skewed in favour of Pfizer Inc. (NYSE:PFE). Shareholder Empowerment Services (SES) has made this suggestion ahead of the shareholder meeting this week. Pfizer Inc. (NYSE:PFE) stock performance was 0.07% in last session and finished the day at $29.89. Traded volume was 30.08million shares in the last session and the average volume of the stock remained 28.52million shares. The beta of the stock remained 0.64. Pfizer Inc. (NYSE:PFE) insider ownership is 0.10%.

Olyzio is being paired with Gilead Sciences Inc. (NASDAQ:GILD)’s new and widely used hepatitis C treatment, Sovaldi. But the J&J brand can expect competition over the next year from other hepatitis C drugs, including a second treatment from Gilead Sciences Inc. (NASDAQ:GILD) that will be combined with Sovaldi in a single pill. Gilead Sciences, Inc. (NASDAQ:GILD) rose 2.07 percent to $68.17 Tuesday on volume of 21.81million shares. The intra-day range of the stock was $65.59 to $69.14. Gilead Sciences, Inc. (NASDAQ:GILD) has a market capitalization of $104.84billion.

The appointment of Hugh M. Cole as the Senior Vice President as well as Chief Business Officer of Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA) has been announced. He would be reporting to Chairman as well as CEO Harvey J. Berger. Cole, who has more than 25 years of experience in the pharma industry, would take up the strategic planning as well as the business development of the company across globe. Ariad Pharmaceuticals, Inc. (NASDAQ:ARIA)’s stock on Apr 15, 2014 reported a decrease of -4.70% to the closing price of $6.69. Its fifty two weeks range is $2.15 -$23.00. The total market capitalization recorded $1.25billion. The overall volume in the last trading session was 17.73million shares. In its share capital, ARIA has 186.33million outstanding shares.

Johnson & Johnson (NYSE:JNJ) reported quarterly earnings well above expectations, as strong sales of new drugs offset weak demand for consumer products and medical devices, and the company slightly raised its full-year profit view. Johnson & Johnson(NYSE:JNJ)’s first-quarter profit rose 8 percent because of restrained costs and a jump in prescription drug sales. The world’s biggest maker of health care products topped Wall Street expectations and raised its earnings outlook. On Tuesday, shares of Johnson & Johnson (NYSE:JNJ) advanced 2.12% to close the day at $99.20. Company return on investment (ROI) is 15.00% and its monthly performance is recorded as 5.61%. Johnson & Johnson (NYSE:JNJ) quarterly revenue growth is 5.49%.